Goldman Sachs Sticks to Its Buy Rating for Insulet (PODD)

Goldman Sachs analyst David Roman maintained a Buy rating on Insulet today and set a price target of $326.00.

President's Day Sale - 70% Off

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

According to TipRanks, Roman is an analyst with an average return of -4.4% and a 37.97% success rate. Roman covers the Healthcare sector, focusing on stocks such as Kestra Medical Technologies Ltd., Carlsmed, Inc., and Baxter International.

In addition to Goldman Sachs, Insulet also received a Buy from Bernstein’s Lee Hambright in a report issued today. However, on the same day, TipRanks – xAI reiterated a Hold rating on Insulet (NASDAQ: PODD).

Based on Insulet’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $706.3 million and a net profit of $87.6 million. In comparison, last year the company earned a revenue of $543.9 million and had a net profit of $77.5 million

Based on the recent corporate insider activity of 64 insiders, corporate insider sentiment is neutral on the stock. Most recently, in December 2025, Frederick Wayne A.I. , a Director at PODD sold 1,851.00 shares for a total of $542,509.59.